An observational study in Schizophrenia, sponsored by University of Oldenburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by University of Oldenburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Schizophrenia with a site in Germany — 17 open to participants now, 21 under way, none of them phase 3. Schizophrenia · Germany.
Among the 179 studies in Schizophrenia with a site in Germany, this one is the 16th largest by enrollment of the 22 observational ones that give a count, is one of 9 that started in 2021, is one of 22 observational ones, and was the 154th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →17 of the 179 studies in Schizophrenia with a site in Germany are open now. Recruiting first, the newest first:
Stephanie Mehl · Sites in Germany
Ages 16–35
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–75
Hannover Medical School · Sites in Germany
Ages 18–65
Technical University of Munich · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 36 · Phase 4 30
First in 2000; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 120 across the 155 interventional studies, 250 across the 22 observational. Of the 139 that completed or were terminated, 25 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 179 have an industry lead sponsor. The 10 most frequent:
University of Oldenburg is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
University of Oldenburg has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
3 of the studies in Schizophrenia with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07265180Charite University, Berlin, GermanyOxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison | 2026-11-30 |
| NCT06740747Hannover Medical SchoolIntermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia | 2026-12-31 |
| NCT06456983Central Institute of Mental Health, MannheimMaintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 179 studies in Schizophrenia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent studies have shown that certain biomarkers of schizophrenia could help to better assess the individual course of the disease and thus, contribute to more personalized treatment options. The aim of the SPIRIT study is to identify potential biomarkers for the prediction of disease-associated outcomes by investigating the neurobiological mechanisms of underlying schizophrenia-related dysfunctions.
Alterations in psychosocial functioning are evident from the prodromal phase of schizophrenia and play a crucial role in its chronic course. While recent studies have demonstrated the predictive validity of structural changes in the brain anatomy of patients with schizophrenia, there is a lack of studies assessing the predictive value of disease-associated alterations in the functional brain activity for symptom severity and psychosocial functioning in schizophrenia.
In this longitudinal, observational study, 60 patients with schizophrenia and 40 healthy subjects without family history of psychotic illness will be recruited to investigate differences in behavioural, physiological, and neural correlates of social touch and interoceptive perception between participant groups. Participants' symptom severity and psychosocial functioning level will be examined by a wide range of behavioural, physiological, and neural methods. Potential biomarkers will be identified by estimating the predictive value of initially performed methods on follow-up re-examination of clinical and psychosocial outcomes. Neural readouts include structural and functional magnetic resonance imaging (fMRI) measurements. The fMRI tasks will probe the processing of social touch and interoceptive perception; additionally resting-state connectivity will be assessed. To further investigate pathological distortions of social touch and interoceptive perception, bodily touch allowance maps will be measured and participants will perform a heart-beat discrimination task. Psychometric questionnaires and semi-structured interviews will be used to capture symptom load and level of psychosocial functioning. Long-term effects will be assessed by online questionnaires and semi-structured interviews via phone call 3- and 6 months after initial assessments. The investigators hypothesize that differences in the neural response to social touch as well as in the neural patterns of interoceptive perception could serve as potential biomarkers for psychosocial deficits during the course of the illness. Furthermore, the inclusion of those biomarkers in predictive models could improve the prediction of disease progression and thus, contribute to personalized therapy.
In- and outpatients of the Department of Psychiatry, University of Oldenburg. Patients meeting the criteria for schizophrenia or schizoaffective disorder according to DSM-V will be included in the study. The patients' diagnosis will be verified via the structured clinical interview for DSM-V. Healthy subjects without family history of psychotic illness (control group). Control group will be matched to the patient sample.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Schizophrenia
Healthy subjects without family history of psychotic illness
Neural responses in a social touch task
Participants will be measured with functional magnetic resonance imaging (fMRI) while they perceive different types of social and non-social touch
Time frame: One-time baseline assessment
Behavioral responses in a social touch fMRI task
Measured as behavioral ratings during the social touch fMRI task. During the social touch fMRI task, participants rate the comfort of the tactile stimuli on a visual analogue scale.
Time frame: One-time baseline assessment
Neural responses in an interoception fMRI task
Participants will be measured with functional magnetic resonance imaging (fMRI) while they perform an interoception task
Time frame: One-time baseline assessment
Behavioral responses in an interoception fMRI task
Measured by performance on the interoception task. During the interoception fMRI task, participants rate how intensely they perceived their heartbeat or their stomach on a visual analogue scale.
Time frame: One-time baseline assessment
Changes in clinician-rated symptom severity between baseline and follow-ups
Measured by half-structured interviews (e.g. Positive and Negative Syndrome Scale (PANSS); range: 30-210; higher scores indicating more severe symptoms) for disease-related symptoms
Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment
Changes in self-reported symptom severity between baseline and follow-ups
Measured by self-evaluation questionnaires (e.g. Self-assessment of Negative Symptoms (SNS); range 1-20; higher scores indicating more severe symptoms) for disease-related symptoms
Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment
Changes in clinician-rated social-role functioning between baseline and follow-ups
Measured by the clinician-rated the social-role functioning scale (range: 1-10; higher scores indicating higher functioning)
Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment
Changes in self-reported social-role functioning levels between baseline and follow-ups
Measured by the self-evaluation questionnaires for social-role functioning (e.g. Social Network Index (SNI); range 1-12; higher scores indicating higher functioning)
Time frame: Baseline, 3 and 6 months follow-up after initial baseline assessment
Bodily maps of social touch
Measured as performance on a bodily maps computer task
Time frame: One-time baseline assessment
Attitude towards social touch
Measured by the self-evaluation questionnaire for social touch tolerance (e.g. Social Touch Questionnaire; range 0-4; higher scores indicating higher touch tolerance)
Time frame: One-time baseline assessment
Interoceptive accuracy
Measured as performance on a heartbeat discrimination task
Time frame: One-time baseline assessment
Interoceptive awareness
Measured by a self-evaluation questionnaire for interoceptive awareness (e.g. Multidimensional Assessment of Interoceptive Awareness (MAIA); range 0-5; higher scores indicating higher interoceptive awareness)
Time frame: One-time baseline assessment
Blood parameter
Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics
Time frame: One-time baseline assessment
Urine parameter
Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics
Time frame: One-time baseline assessment
Neural activity at resting state
fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open.
Time frame: One-time baseline assessment
Structural connectivity measure
fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open.
Time frame: One-time baseline assessment
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in May 2024, 32 months.
Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's 32 months is below that.
Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oldenburg